i-SENS, Inc.

KOSDAQ 099190.KQ

i-SENS, Inc. EBITDA Margin for the year ending December 31, 2023: 8.55%

i-SENS, Inc. EBITDA Margin is 8.55% for the year ending December 31, 2023, a -28.90% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

i-SENS, Inc. EBITDA Margin for the year ending December 31, 2022 was 12.03%, a -37.34% change year over year.
i-SENS, Inc. EBITDA Margin for the year ending December 31, 2021 was 19.20%, a -5.47% change year over year.
i-SENS, Inc. EBITDA Margin for the year ending December 31, 2020 was 20.31%, a -4.06% change year over year.
i-SENS, Inc. EBITDA Margin for the year ending December 31, 2019 was 21.17%, a 3.94% change year over year.

Key data

Date	EBITDA Margin	EBIT Margin	Depreciation and Amortization	EBIT

KOSDAQ: 099190.KQ

i-SENS, Inc.

CEO	Dr. Geun-Sig Cha
IPO Date	Jan. 30, 2013
Location	South Korea
Headquarters	43, Banpo-daero 28-gil
Employees	687
Sector	Consumers Staples
Industries Personal Care Biotechnology Frozen Foods Hardware & Electronics Medical Instruments Non-Alcoholic Beverages Pharmaceuticals Telehealth

Description

i-SENS, Inc. provides diagnostic biosensors in South Korea. The company offers point of care testing devices, such as HbA1c, blood gas, electrolyte, and PT/INR analyzers; CareSens blood glucose monitoring systems; and lancing and other ancillary devices, as well as diabetes management services. It exports its products to approximately 110 countries, including the United States, Japan, and Europe. The company was founded in 2000 and is headquartered in Seoul, South Korea.

Key trends

Past 5 years